Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328132 | Acta Haematologica Polonica | 2015 | 53 Pages |
Abstract
New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. Therapeutic regimens based on bortezomib, thalidomide and lenalidomide are recommended to most patients in first line therapy. Induction therapy should be accompanied with prolonged treatment composed of consolidation and maintenance. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease as well as transplantation procedure offered to older, fit patients. In this article we also described therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Anna Dmoszyńska, Adam Walter-Croneck, Lidia Usnarska-Zubkiewicz, Beata Stella-Hołowiecka, Jan Walewski, Grzegorz Charliński, Wiesław Wiktor Jędrzejczak, Elżbieta Wiater, Ewa Lech-Marańda, Dominik Dytfeld, Mieczysław Komarnicki, Krzysztof Jamroziak,